Artwork

Innhold levert av Talking About Tumors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Talking About Tumors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

02_02 Chemotherapy Options and Bisphosphonates in Early Breast Cancer

25:09
 
Del
 

Manage episode 343735703 series 3335024
Innhold levert av Talking About Tumors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Talking About Tumors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

1. First, second, and third generation chemotherapy regimens

2. Considerations for anthracyclines

3. Considerations for taxanes

4. Adjuvant bisphosphonates

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1. Budd GT et al. J Clin Oncol. 2015;33(1):58-64. doi:10.1200/JCO.2014.56.3296

2. Citron ML et al. J Clin Oncol. 2003;21(8):1431-1439. doi:10.1200/JCO.2003.09.081

3. Anampa J, Makower D, Sparano JA. BMC Med. 2015;13(1). doi:10.1186/S12916-015-0439-8

4. Sparano JA et al. J Clin Oncol. 2015;33(21):2353-2360. doi:10.1200/JCO.2015.60.9271

5. Coleman R et al. Lancet. 2015;386(10001):1353-1361. doi:10.1016/S0140-6736(15)60908-4

6. Gray R et al. Lancet. 2019;393(10179):1440-1452. doi:10.1016/S0140-6736(18)33137-4

7. Abe O et al. Lancet. 2005;365(9472):1687-1717. doi:10.1016/S0140-6736(05)66544-0

8. Albain K et al. Lancet. 2012;379(9814):432. doi:10.1016/S0140-6736(11)61625-5

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

49 episoder

Artwork
iconDel
 
Manage episode 343735703 series 3335024
Innhold levert av Talking About Tumors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Talking About Tumors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

1. First, second, and third generation chemotherapy regimens

2. Considerations for anthracyclines

3. Considerations for taxanes

4. Adjuvant bisphosphonates

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1. Budd GT et al. J Clin Oncol. 2015;33(1):58-64. doi:10.1200/JCO.2014.56.3296

2. Citron ML et al. J Clin Oncol. 2003;21(8):1431-1439. doi:10.1200/JCO.2003.09.081

3. Anampa J, Makower D, Sparano JA. BMC Med. 2015;13(1). doi:10.1186/S12916-015-0439-8

4. Sparano JA et al. J Clin Oncol. 2015;33(21):2353-2360. doi:10.1200/JCO.2015.60.9271

5. Coleman R et al. Lancet. 2015;386(10001):1353-1361. doi:10.1016/S0140-6736(15)60908-4

6. Gray R et al. Lancet. 2019;393(10179):1440-1452. doi:10.1016/S0140-6736(18)33137-4

7. Abe O et al. Lancet. 2005;365(9472):1687-1717. doi:10.1016/S0140-6736(05)66544-0

8. Albain K et al. Lancet. 2012;379(9814):432. doi:10.1016/S0140-6736(11)61625-5

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

49 episoder

すべてのエピソード

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2025 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett
Lytt til dette showet mens du utforsker
Spill